<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SARGRAMOSTIM (GM-CSF)</span><br/>(sar-gra'mos-tim)<br/><span class="topboxtradename">Leukine, </span><span class="topboxtradename">Leukine Liquid, </span><span class="topboxtradename">Prokine<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators and anticoagulants</span>; <span class="classification">hematopoietic growth factor</span><br/><b>Prototype: </b>Epoetin alfa<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mcg, 500 mcg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) produced by recombinant DNA technology in a yeast.
         GM-CSF is a hematopoietic growth factor that stimulates proliferation and differentiation of hematopoietic progenitor cells
         in the granulocyte-macrophage pathways.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases the cytotoxicity of monocytes to certain neoplastic cell lines and activates polymorphonuclear neutrophils (PMNs)
         to inhibit the growth of tumor cells.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Myeloid reconstitution after autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma (NHL), acute
         lymphoblastic leukemia (ALL), and Hodgkin's disease; mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To increase WBC counts in AIDS patients; to decrease leukopenia secondary to myelosuppressive chemotherapy; to correct neutropenia
         in aplastic anemia and in liver and kidney transplantations.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Excessive leukemic myeloid blasts in bone marrow or blood; known hypersensitivity to GM-CSF or yeast products.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of cardiac arrhythmias, preexisting cardiac disease, hypoxia, CHF, pulmonary infiltrates; kidney and liver dysfunction;
         pregnancy (category C), lactation. Safety and efficacy in children are not established; however, adverse side effects have
         been comparable to those in adults.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Autologous Bone Marrow Transplant</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 250 mcg/m<sup>2</sup>/d infused over 2 h for 21 d, begin 24 h after bone marrow transfusion and not less than 24 h after last dose of chemotherapy
               or 12 h after last radiation therapy<br/><span class="rdage">Child:</span> <span class="rdroute">IV/SC</span> 250 mcg/m<sup>2</sup>/d times 21 d, begin 24 h after bone marrow infusion or not less than 24 h after chemotherapy<br/><br/><span class="indicationtitle">Neutropenia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">SC</span> 315 mcg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li> 				Note: Do not give within 24 h preceding or following chemotherapy or within 12 h preceding or following radiotherapy. 			</li>
</ul><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute each 250 or 500 mcg vial with 1 mL of sterile water for injection (without preservative). Direct sterile water
            against side of vial and swirl gently. Avoid excessive or vigorous agitation. Do not shake. Use without further dilution for
            SC injection.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 					Note: Verify correct IV concentration and rate of infusion administration in infants and children with physician. 				</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute as for SC, then further dilute reconstituted solution with NS. If the final concentration is 
               </p><p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give over 2 h. Do not use an in-line membrane filter.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Hydrocortisone,</b> <b>hydroxyzine,</b> <b>haloperidol.</b> <span class="incompattype">Y-site:</span> <b>Acyclovir,</b> <b>amphotericin B,</b> <b>ampicillin,</b> <b>ampicillin/sulbactam,</b> <b>amsacrine,</b> <b>cefonicid,</b> <b>cefoperazone,</b> <b>chlorpromazine,</b> <b>ganciclovir,</b> <b>haloperidol,</b> <b>hydrocortisone,</b> <b>hydromorphone,</b> <b>hydroxyzine,</b> <b>idarubicin,</b> <b>imipenem/cilastatin,</b> <b>lorazepam,</b> <b>methylprednisolone,</b> <b>mitomycin,</b> <b>morphine,</b> <b>nalbuphine,</b> <b>ondansetron,</b> <b>piperacillin,</b> <b>sodium bicarbonate,</b> <b>tobramycin.</b>
</p>
<ul>
<li>Interrupt administration and reduce the dose by 50% if absolute neutrophil count exceeds 20,000/mm<sup>3</sup> or if platelet count exceeds 500,000/mm<sup>3</sup>. Notify physician.
                  </li>
<li>Reduce the IV rate 50% if patient experiences dyspnea during administration. Discontinue infusion if respiratory symptoms
                     worsen. Notify physician.
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Refrigerate the sterile powder, the reconstituted solution, and store diluted solution at 2°8° C (36°46°
            F). Do not freeze or shake.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Lethargy, malaise, headache, fatigue. <span class="typehead">CV:</span> Abnormal ST segment depression, supraventricular arrhythmias, edema, <span class="speceff-common">hypotension, tachycardia,</span> <span class="speceff-life">pericardial effusion</span>, pericarditis. <span class="typehead">Hematologic:</span> Anemia, <span class="speceff-common">thrombocytopenia.</span> <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, anorexia. <span class="typehead">Body as a Whole:</span> <span class="speceff-common">Bone pain, myalgia, arthralgias,</span> weight gain, hyperuricemia, <span class="speceff-common">fever.</span> <span class="typehead">Respiratory:</span> Pleural effusion. <span class="typehead">Skin:</span> <span class="speceff-common">Rash, pruritus.</span> <span class="typehead">Other:</span> <span class="speceff-common">First-dose reaction</span> (some or all of the following symptoms: hypotension, tachycardia, fever, rigors, flushing, nausea, vomiting, diaphoresis,
      back pain, leg spasms, and dyspnea). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">corticosteroids</span> should be used cautiously with sargramostim because the myeloproliferative effects may be potentiated. <b>Lithium</b> should be used with caution with sargramostim because it may potentiate the myeloproliferative effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from SC site. <span class="typehead">Onset:</span> 36 h. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 510 d SC. <span class="typehead">Elimination:</span> Probably excreted in urine. <span class="typehead">Half-Life:</span> 80150 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain a CBC and platelet count prior to initiation of therapy. Monitor biweekly CBC with differential during therapy.
            Monitor kidney and liver function biweekly in patients with kidney or liver dysfunction prior to the initiation of therapy.
         </li>
<li>Discontinue treatment if WBC 50,000/mm<sup>3</sup>. Notify the physician.
         </li>
<li>Occasional transient supraventricular arrhythmias have occurred during administration, particularly in those with a history
            of cardiac arrhythmias. Arrhythmias are reversed with discontinuation of drug.
         </li>
<li>Give special attention to respiratory symptoms (dyspnea) during and immediately following infusion, especially in patients
            with preexisting pulmonary disease.
         </li>
<li>Use drug with caution in patients with preexisting fluid retention, pulmonary infiltrates, or CHF. Peripheral edema, pleural
            or pericardial effusion has occurred after administration. It is reversible with dose reduction.
         </li>
<li>Notify physician of any severe adverse reaction immediately.</li>
<li>Discontinue therapy and notify physician if disease progression is detected. Potentially, drug can act as a growth factor
            for myeloid malignancies.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify nurse or physician immediately of any adverse effect (e.g., dyspnea, palpitations, peripheral edema, bone or muscle
            pain) during or after drug administration.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>